Topics

AEVIS VICTORIA SA: Strong revenue growth in the third quarter; Swiss Medical Network and Victoria-Jungfrau Collection continue to register organic growth

03:00 EDT 29 Oct 2019 | EQS Group

AEVIS VICTORIA SA / Key word(s): 9 Month figures

29-Oct-2019 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Press release

Fribourg, 29 October 2019

AEVIS VICTORIA SA: Strong revenue growth in the third quarter; Swiss Medical Network and Victoria-Jungfrau Collection continue to register organic growth

As at 30 September 2019, total revenues of AEVIS VICTORIA SA amounted to CHF 707.6 million (2018: CHF 469.1 million), including the gain on the sale of the Infracore stake of CHF 193.8 million. Net revenues (medical fees excluded) amounted to CHF 643.1 million, up by 56.4% compared to 2018 (CHF 411.3 million). Operating revenues increased by 9.5%, driven in particular by the strong performance in the hospital segment. Acquisitions excluded, organic growth reached 5.8% at group level and 6.3% for the hospital segment.

Swiss Medical Network realised total revenues of CHF 449.9 million compared to CHF 409.4 million in 2018. Net revenues amounted to CHF 385.9 million, representing an increase of 9.6% compared to last year (CHF 352.1 million). On a like-for-like basis, Swiss Medical Network achieved organic growth of 6.3%, despite the shift to outpatient care and a reduction in TARMED tariffs. Klinik Belair in Schaffhausen, acquired from the Hirslanden Group, will be consolidated in Swiss Medical Network as of 1 October 2019. Swiss Medical Network pursues its growth policy through acquisitions and its optimisation and cost reduction programme initiated in 2018.

Victoria-Jungfrau Collection, the hospitality segment of AEVIS VICTORIA, generally performed well in a dynamic market environment. Total revenues reached CHF 49.9 million, compared to CHF 48.8 million last year, implying an organic growth of 2.3%. After the period under review, following the acquisition of 100% of Seiler & Partenaires Holding SA, Mont Cervin Palace and Hotel Monte Rosa were added to the luxury hotel portfolio. Hotel Eden au Lac, closed for complete renovation since October 2017, will reopen on 1 December 2019 under the brand name La Réserve Eden au Lac Zurich.

Outlook
Fourth quarter 2019 revenues will increase sharply following the acquisitions in the hospitality segment, the reopening of La Réserve Eden au Lac Zurich and the acquisition of Klinik Belair.

AEVIS favors investments as a reference shareholder in companies active in its focus sectors. As an active investor, AEVIS exerts significant influence on the strategies of the companies it holds shares in, leaving them with full responsibility for operational management. AEVIS will continue to collaborate with other market players in order to further develop and grow the activities of its participations, as it has been done for Infracore.

AEVIS wishes to offer its shareholders a combination of capital gains generated by value creation in its subsidiaries and a stable annual return. It is expected that the ordinary distribution will be substantially increased for the 2019 financial year.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Philippe R. Blangey, prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 or +41 (0) 79 785 46 32
Séverine Van der Schueren, svanderschueren@aevis.com, +41 (0) 79 635 04 10


AEVIS VICTORIA SA - Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA, the second largest group of private hospitals in Switzerland, Victoria-Jungfrau Collection AG, a luxury hotel group managing four luxury hotels in Switzerland, Infracore SA (19%), a real estate company dedicated to healthcare-related infrastructure, a hospitality real estate division, Medgate (40%), the leading telemedicine provider in Switzerland, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.



End of ad hoc announcement
show this

Original Article: AEVIS VICTORIA SA: Strong revenue growth in the third quarter; Swiss Medical Network and Victoria-Jungfrau Collection continue to register organic growth

NEXT ARTICLE

More From BioPortfolio on "AEVIS VICTORIA SA: Strong revenue growth in the third quarter; Swiss Medical Network and Victoria-Jungfrau Collection continue to register organic growth"

Quick Search

Relevant Topics

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.